IDH1 and acute myeloid leukemia: AEs of an IDH1/2 mutation inhibitor occurred in 5–20% of patients in an AML clinical trial [151], which include QT interval prolongation (which might trigger sudden fainting) and leukocytosis, indirect hyperbilirubinemia, thrombocytopenia, etc. [152].